Dextran

Identification

Name
Dextran
Accession Number
DB09255
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

Dextran is a polysaccharide that differs from others in that its glucose units are joined together 1:6 glucoside links. The main chain of glucose has short branches at frequent intervals which are probably joined by 1:3 and 1:4 glucoside links. The chains can be composed of about 200,000 glucose units.[2] Many bacteria, like Leuconostoc, can synthesize dextran from sucrose, and this activity is used commercially to obtain dextran.[5]

Dextran 40 is a sterile, nonpyrogenic preparation of low molecular weight dextran (average mol. wt. 40,000) in 5% Dextrose Injection or 0.9% Sodium Chloride Injection. It is administered by intravenous infusion.

Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. It is produced from certain bacteria that with α-1,6 glycosidic linkages between glucose molecules and α-1,3 linkages between branches. When labelled with technetium Tc99m, dextran 75 is intravenously administered as an imaging agent to detect and diagnose conditions in the vascular compartment such as pericardial effusion or ventricular aneurysm.

Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Dextran 40K3R6ZDH4DUNot AvailableNot applicable
Dextran 707SA290YK68Not AvailableNot applicable
Dextran 75JY83SHX053Not AvailableNot applicable
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LMD in DextroseInjection, solution10 g/100mLIntravenousHospira, Inc.1992-10-30Not applicableUs
LMD in Sodium ChlorideInjection, solution10 g/100mLIntravenousHospira, Inc.1992-10-30Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Artificial TearsDextran (0.1 %) + Hypromellose (0.3 %)SolutionOphthalmicAlcon, Inc.2005-03-162009-02-24Canada
Dextran 6% In 0.9% Sodium Chloride InjectionDextran (60 mg) + Sodium Chloride (9 mg)SolutionIntravenousHospira, Inc.1955-12-312012-08-03Canada
Dextran 6% In 5% Dextrose InjectionDextran (60 mg) + Dextrose, unspecified form (50 mg)SolutionIntravenousHospira, Inc.1955-12-312012-08-03Canada
Gentran 40 10% Dextrose 5% InjDextran (10 g) + Dextrose, unspecified form (5 g)LiquidIntravenousBaxter Laboratories1979-12-312008-05-23Canada
Gentran 40 10% Sodium Chloride 0.9% InjDextran (10 g) + Sodium Chloride (900 mg)LiquidIntravenousBaxter Laboratories1979-12-312008-05-23Canada
Gentran-70 6% & Sodium Chloride 0.9% InjDextran (6 %) + Sodium Chloride (.9 %)SolutionIntravenousBaxter Laboratories1992-12-312008-05-23Canada
Lmd 10% In 0.9% Sodium ChlorideDextran (10 %) + Sodium Chloride (0.9 %)SolutionIntravenousPfizer1968-12-31Not applicableCanada
Lmd 10% In Dextrose 5%Dextran (10 %) + Dextrose, unspecified form (5 %)SolutionIntravenousPfizer1968-12-31Not applicableCanada
Macrodex 6% In DextroseDextran (6 g) + Dextrose, unspecified form (5 g)LiquidIntravenousPharmacia1962-12-311996-09-10Canada
Macrodex 6% In Normal SalineDextran (6 g) + Sodium Chloride (900 mg)LiquidIntravenousPharmacia1962-12-311996-09-10Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Dextran 75Dextran 75 (10 mg/1)Injection, powder, lyophilized, for solutionIntravenousAnazao Health Corporation2012-07-01Not applicableUs
Categories
UNII
Not Available
CAS number
9004-54-0
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Dextran is used as the restoration of blood mass during surgical interventions if there is hypovolemia due to trauma or dehydration. It is as well used after the presence of hemorrhage in cases of blood loss to a level inferior to 15% of the blood mass, if compatibility test cannot be completed or when blood lots need to be tested for pathogen detection. Dextran is also used for the prevention of profound postoperative venous thrombosis.[9]

Dextran as well presents ophthalmic applications as solutions or ointments for the temporary relief of xerophthalmia or minor ocular irritations.[10]

Associated Conditions
Associated Therapies
Pharmacodynamics

It is reported that dextran presents an effect on the hemostatic system in particular by prolonging bleeding time. In the same trials, dextran is reported to reduce emboli, reduce platelet adhesiveness and produce hemodilution. These effects have been showed to be greater proportionally with the increase in the molecular weight of the dextran.[3]

Mechanism of action

In preclinical studies, the mechanism of action is thought to be related to the blockage of the uptake of tissue plasminogen activator by mannose-binding receptors. This process has a direct effect by enhancing endogenous fibrinolysis.[3]

Absorption

Dextran presents a very low oral bioavailability that is reduced as the chain gets longer. Thus, the bioavailability of dextran is inversely proportional to the length of the carbohydrate chain.[5]

Volume of distribution

The reported volume of distribution of dextran suggested a distribution throughout the blood volume. This volume of distribution is reported to be of around 120 ml. The organ that presented a higher accumulation of dextran was the liver.[11]

Protein binding

Dextran is highly retained in the vascular system by binding to plasma proteins including albumin.[9]

Metabolism

Long chains of dextran such as dextran 60 are highly metabolized in the liver until formation of lower molecular weight products before being excreted from the body.[5]

Route of elimination

The elimination of dextran will depend on the length of the carbohydrate chain, the administration route, and the molecular weight. For dextran 1, it is reported to be mainly secreted unchanged in the urine in a ratio of 80% of the administered dose when administered parentally. It is registered that the weight threshold for unrestricted glomerular filtration is about 15 kDa and if the dextran overpasses 50 kDa it will not be renally eliminated in any significant amount.[5]

Half life

The elimination half-life will depend on the length of the carbohydrate chain. The higher the molecular weight of the dextran the longer it will be the elimination half-life. The half-life will go from 1.9 hours from dextran 1 to 42 hours in the case of dextran 60.[4, 5]

Clearance
Not Available
Toxicity

Some reports have shown adverse effects when used in therapeutical doses and some teratogenic effects have been demonstrated when used in large doses. The current LD50 reported in rats is 10700 mg/kg.[5]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Dextran.Investigational
AbciximabDextran may increase the anticoagulant activities of Abciximab.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Dextran.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Dextran is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Dextran.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Dextran.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Dextran.Approved, Withdrawn
AllylestrenolThe therapeutic efficacy of Dextran can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Dextran.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Dextran.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Dextran.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Dextran.Approved
AltrenogestThe therapeutic efficacy of Dextran can be decreased when used in combination with Altrenogest.Vet Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Dextran.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Dextran.Approved
AncrodAncrod may increase the anticoagulant activities of Dextran.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Dextran.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Dextran.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Dextran.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Dextran.Approved, Investigational
Antithrombin III humanDextran may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Dextran.Approved
ApocyninApocynin may increase the anticoagulant activities of Dextran.Investigational
ApremilastApremilast may increase the anticoagulant activities of Dextran.Approved, Investigational
ArdeparinArdeparin may increase the anticoagulant activities of Dextran.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Dextran.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Dextran.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Dextran.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Dextran.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Dextran is combined with Azficel-T.Approved, Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Dextran.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Dextran.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Dextran.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Dextran.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Dextran.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Dextran.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Dextran.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Dextran.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Dextran.Approved
BeraprostBeraprost may increase the anticoagulant activities of Dextran.Investigational
BevoniumBevonium may increase the anticoagulant activities of Dextran.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Dextran.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Dextran.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Dextran.Approved
BucillamineBucillamine may increase the anticoagulant activities of Dextran.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Dextran.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Dextran.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Dextran.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Dextran.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Dextran.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Dextran.Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Dextran.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Dextran.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Dextran.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Dextran.Approved, Investigational
CertoparinDextran may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlormadinoneThe therapeutic efficacy of Dextran can be decreased when used in combination with Chlormadinone.Experimental
ChloroquineChloroquine may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Dextran.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Dextran.Approved
CilostazolCilostazol may increase the anticoagulant activities of Dextran.Approved, Investigational
Citric AcidCitric Acid may increase the anticoagulant activities of Dextran.Approved, Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Dextran.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Dextran.Approved
CloricromenCloricromen may increase the anticoagulant activities of Dextran.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Dextran.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Dextran is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Dextran.Approved
CurcuminCurcumin may increase the anticoagulant activities of Dextran.Approved, Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Dextran.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Dextran.Experimental
DalteparinDalteparin may increase the anticoagulant activities of Dextran.Approved
DanaparoidDanaparoid may increase the anticoagulant activities of Dextran.Approved, Withdrawn
DarexabanDextran may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Dextran.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Dextran is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Dextran.Approved, Investigational
DemegestoneThe therapeutic efficacy of Dextran can be decreased when used in combination with Demegestone.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Dextran is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Dextran.Investigational
DesirudinDextran may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Dextran.Investigational
DesogestrelThe therapeutic efficacy of Dextran can be decreased when used in combination with Desogestrel.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Dextran.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Dextran.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Dextran.Approved, Investigational
DienogestThe therapeutic efficacy of Dextran can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Dextran.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Dextran.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Dextran.Approved, Investigational
DiphenadioneDiphenadione may increase the anticoagulant activities of Dextran.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Dextran.Approved
DitazoleDitazole may increase the anticoagulant activities of Dextran.Approved, Withdrawn
DrospirenoneThe therapeutic efficacy of Dextran can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Dextran.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Dextran.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Dextran.Investigational
DydrogesteroneThe therapeutic efficacy of Dextran can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Dextran.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Dextran.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Dextran.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Dextran.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Dextran.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Dextran.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Dextran.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Dextran.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Dextran.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Dextran.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Dextran.Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Dextran.Approved
EstroneEstrone may decrease the anticoagulant activities of Dextran.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Dextran.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Dextran.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Dextran.Approved
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Dextran.Withdrawn
EthynodiolThe therapeutic efficacy of Dextran can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Dextran.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Dextran can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Dextran.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Dextran.Investigational, Nutraceutical
ExisulindExisulind may increase the anticoagulant activities of Dextran.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Dextran.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Dextran.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Dextran.Approved
FentiazacFentiazac may increase the anticoagulant activities of Dextran.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Dextran.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Dextran.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Dextran.Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Dextran.Approved, Withdrawn
FluindioneDextran may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Dextran.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Dextran.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Dextran.Approved, Investigational
FondaparinuxFondaparinux sodium may increase the anticoagulant activities of Dextran.Approved, Investigational
GabexateDextran may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Dextran.Investigational
GestodeneThe therapeutic efficacy of Dextran can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Dextran can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Dextran can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Dextran.Experimental
HeminHemin may increase the anticoagulant activities of Dextran.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Dextran.Experimental
HeparinHeparin may increase the anticoagulant activities of Dextran.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Dextran.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Dextran.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Dextran can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Dextran.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Dextran is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dextran.Approved
IbudilastIbudilast may increase the anticoagulant activities of Dextran.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Dextran.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Dextran.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Dextran.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Dextran.Approved, Investigational, Nutraceutical
IdraparinuxIdraparinux may increase the anticoagulant activities of Dextran.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Dextran.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Dextran.Investigational
IloprostIloprost may increase the anticoagulant activities of Dextran.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Dextran.Experimental
IndobufenIndobufen may increase the anticoagulant activities of Dextran.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Dextran.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Dextran.Withdrawn
IsoxicamIsoxicam may increase the anticoagulant activities of Dextran.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Dextran.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Dextran.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Dextran.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Dextran.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Dextran.Approved, Investigational
LepirudinDextran may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanDextran may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Dextran can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Dextran.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Dextran.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Dextran.Investigational
LonazolacLonazolac may increase the anticoagulant activities of Dextran.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Dextran.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Dextran.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Dextran.Approved, Investigational
LynestrenolThe therapeutic efficacy of Dextran can be decreased when used in combination with Lynestrenol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Dextran.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Dextran.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Dextran can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Dextran can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Dextran.Approved
Megestrol acetateThe therapeutic efficacy of Dextran can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranDextran may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Dextran.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Dextran.Approved
MestranolMestranol may decrease the anticoagulant activities of Dextran.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Dextran.Approved, Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Dextran.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Dextran can be decreased when used in combination with Methylestrenolone.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Dextran.Approved
MizoribineMizoribine may increase the anticoagulant activities of Dextran.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Dextran.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Dextran.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Dextran.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Dextran.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Dextran.Approved
NadroparinNadroparin may increase the anticoagulant activities of Dextran.Approved, Investigational
NafamostatNafamostat may increase the anticoagulant activities of Dextran.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Dextran.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Dextran.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Dextran.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Dextran.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Dextran.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Dextran.Approved
NimesulideNimesulide may increase the anticoagulant activities of Dextran.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Dextran is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Dextran.Investigational
NomegestrolThe therapeutic efficacy of Dextran can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Dextran can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Dextran can be decreased when used in combination with Norgestrienone.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Dextran is combined with Obinutuzumab.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Dextran.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Dextran.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Dextran is combined with Omacetaxine mepesuccinate.Approved, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Dextran.Approved, Nutraceutical
Omega-3-carboxylic acidsThe therapeutic efficacy of Dextran can be increased when used in combination with Omega-3-carboxylic acids.Approved, Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Dextran.Vet Approved
OtamixabanOtamixaban may increase the anticoagulant activities of Dextran.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Dextran.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Dextran.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Dextran.Investigational
PalmidrolPalmidrol may increase the anticoagulant activities of Dextran.Experimental, Nutraceutical
ParecoxibParecoxib may increase the anticoagulant activities of Dextran.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Dextran.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Dextran.Approved, Investigational
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Dextran.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Dextran.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Dextran.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Dextran.Approved, Investigational
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Dextran.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Dextran.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Dextran.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Dextran.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Dextran.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Dextran.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Dextran.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Dextran.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Dextran.Approved
Potassium CitrateDextran may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Dextran.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Dextran.Approved
ProgesteroneThe therapeutic efficacy of Dextran can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Dextran.Experimental
PromegestoneThe therapeutic efficacy of Dextran can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Dextran.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Dextran.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Dextran.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Dextran.Experimental
Protein CDextran may increase the anticoagulant activities of Protein C.Approved
Protein S humanDextran may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDextran may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Dextran.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Dextran.Approved
QuingestanolThe therapeutic efficacy of Dextran can be decreased when used in combination with Quingestanol.Experimental
RamatrobanRamatroban may increase the anticoagulant activities of Dextran.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Dextran.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Dextran.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Dextran.Approved, Investigational
ReviparinDextran may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Dextran.Approved
RivaroxabanDextran may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Dextran.Approved, Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Dextran.Approved, Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Dextran.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Dextran.Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Dextran.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Dextran.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Dextran.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Dextran.Approved
SemapimodSemapimod may increase the anticoagulant activities of Dextran.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Dextran.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Dextran.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Sodium CitrateDextran may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
SRT501SRT501 may increase the anticoagulant activities of Dextran.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Dextran.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Dextran.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Dextran.Approved
SulindacSulindac may increase the anticoagulant activities of Dextran.Approved, Investigational
SulodexideSulodexide may increase the anticoagulant activities of Dextran.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Dextran.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Dextran.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Dextran.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dextran.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Dextran.Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Dextran.Approved
TenidapTenidap may increase the anticoagulant activities of Dextran.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Dextran.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Dextran.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Dextran.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Dextran.Investigational
Testosterone cypionateThe therapeutic efficacy of Dextran can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Dextran can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Dextran can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Dextran.Approved
TiboloneTibolone may increase the anticoagulant activities of Dextran.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Dextran.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Dextran.Approved
TinoridineTinoridine may increase the anticoagulant activities of Dextran.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Dextran.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Dextran.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Dextran.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Dextran.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Dextran.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Dextran.Approved
TositumomabThe risk or severity of adverse effects can be increased when Dextran is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Dextran.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Dextran.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Dextran.Approved, Investigational
TribenosideTribenoside may increase the anticoagulant activities of Dextran.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Dextran.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Dextran.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Dextran.Approved
TroxerutinDextran may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Dextran.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Dextran.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the anticoagulant activities of Dextran.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Dextran.Approved
WarfarinWarfarin may increase the anticoagulant activities of Dextran.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Dextran.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Dextran.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Dextran.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Dextran.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Dextran.Withdrawn
Food Interactions
Not Available

References

General References
  1. Klotz U, Kroemer H: Clinical pharmacokinetic considerations in the use of plasma expanders. Clin Pharmacokinet. 1987 Feb;12(2):123-35. [PubMed:2435442]
  2. RICKETTS CR: Chemistry of dextran and its derivatives. Proc R Soc Med. 1951 Jul;44(7):558-9. [PubMed:14864546]
  3. Jones CI, Payne DA, Hayes PD, Naylor AR, Bell PR, Thompson MM, Goodall AH: The antithrombotic effect of dextran-40 in man is due to enhanced fibrinolysis in vivo. J Vasc Surg. 2008 Sep;48(3):715-22. doi: 10.1016/j.jvs.2008.04.008. Epub 2008 Jun 24. [PubMed:18572351]
  4. Gray A., Wright J., Goodey V. and Bruce L. (2011). Injectable drugs guide. Royal pharmaceutical society .
  5. Collins P. (2006). Dictionary of carbohydrates (2nd ed.). Taylor and Francis.
  6. Dailymed [Link]
  7. Drugs.com [Link]
  8. ChemIDplus [Link]
  9. WHO [Link]
  10. Tears naturale monograph [Link]
  11. Military trauma research [Link]
External Links
KEGG Drug
D00060
KEGG Compound
C00372
PubChem Substance
347910421
Wikipedia
Dextran
ATC Codes
B05AA05 — Dextran
MSDS
Download (39.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingPreventionKeratolysis1
2CompletedTreatmentConjunctivitis, Seasonal Allergic1
2, 3CompletedTreatmentAKI / Liver Cirrhosis1
3Active Not RecruitingTreatmentCorneal Ectasia / Keratoconus1
3Active Not RecruitingTreatmentPhenylketonuria (PKU)1
3CompletedTreatmentConjunctivitis, Viral1
3CompletedTreatmentEye Dryness1
3Unknown StatusTreatmentAdenovirus / Conjunctivitis1
4CompletedTreatmentAnterior Uveitis (AU) / Cystoid Macular Edema1
4CompletedTreatmentConjunctivitis, Seasonal Allergic3
4TerminatedTreatmentSpontaneous Bacterial Peritonitis (SBP)1
4Unknown StatusDiagnosticEye Dryness1
4WithdrawnTreatmentDry Eye Syndrome (DES)1
Not AvailableCompletedPreventionEye Dryness1
Not AvailableCompletedTreatmentDry Eye Syndrome (DES)1
Not AvailableCompletedTreatmentEye Dryness1
Not AvailableCompletedTreatmentEye Dryness / Lipid Layer / Liposic / Tear Film / Tears Naturale Forte1
Not AvailableCompletedTreatmentIntraocular Pressure1
Not AvailableCompletedTreatmentMigraines1
Not AvailableRecruitingTreatmentAdenoviral Conjunctivitis / Conjunctivitis1
Not AvailableRecruitingTreatmentAge-related Cataract1
Not AvailableRecruitingTreatmentEye Dryness1
Not AvailableRecruitingTreatmentMeibomian Gland Dysfunction (MGD) / Sjögren's Syndrome2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionOphthalmic
Injection, powder, lyophilized, for solutionIntravenous10 mg/1
SolutionIntravenous
Injection, solutionIntravenous10 g/100mL
LiquidIntravenous
LiquidOphthalmic
Solution / dropsOphthalmic
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)>254ºC'MSDS'
water solubilitySoluble 'MSDS'
logP0Loftsson T. Essential pharmacokinetics. (2015)
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 26, 2015 10:05 / Updated on August 02, 2018 06:16